The impact of proton pump inhibitor exposure on pneumonia: an updated meta-analysis based on randomized controlled trials
Frontiers in Pharmacology · 28.10.2025 · 16
DOI: 10.3389/fphar.2025.1713256 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 28.10.2025. Verfasst von Zhujun Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Ningbo Zhenhai Hospital of Traditional Chinese Medicine, Ningbo, Zhejiang, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The association between proton pump inhibitor (PPI) use and pneumonia risk remains inconclusive. This meta-analysis explores the impact of PPI use on the risk of pneumonia.
Methods
We systematically searched for relevant randomized controlled trials in PubMed, Web of Science, EMBASE and Cochrane Library from January 2000 to March 2025. Relative ratio and 95% confidence interval were calculated to quantify the association between proton pump inhibitor use and pneumonia incidence.
Results
The analysis included 20 RCTs involving 29,100 participants. Compared to the non-PPI group, the PPI-exposed group showed a higher incidence of pneumonia in the general population (RR = 1.10, 95% CI: 0.99-1.21, p = 0.07) and for hospital-acquired pneumonia (HAP) (RR = 1.12, 95% CI: 1.00-1.26, p = 0.06), although the differences were not statistically significant. A higher incidence of pneumonia was observed in the intervention group among the Asian population (RR = 1.30, p = 0.02), particularly in Iran (RR = 2.73, p < 0.001) and among Asian users of pantoprazole (RR = 1.94, p = 0.05). No significant differences in pneumonia incidence were found between groups among participants from Europe (RR = 1.04, p = 0.67) or America (RR = 1.02, p = 0.95), for ventilator-associated pneumonia (VAP) (RR = 1.17, p = 0.11), or among participants in intensive care units (ICUs) (RR = 1.05, p = 0.29) or out of ICUs (RR = 1.28, p = 0.14).
Conclusion
The use of PPI might increase the risk of pneumonia in general population, especially among Asians (in Iran and in the Asian users of pantoprazole), HAP. Systematic Review Registration Identifier, CRD420251021884.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Ningbo Zhenhai Hospital of Traditional Chinese Medicine, Ningbo, Zhejiang, China.
- The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
- The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
- Department of Respiratory and Critical Care Medicine, Ningbo Yinzhou No. 2 Hospital, , Ningbo, Zhejiang, China.
Zitieren
APA
Wu, Z., Wu, Y., Xiang, Z., Qiu, Y., Xuan, W., & Zhang, S. (2025). The impact of proton pump inhibitor exposure on pneumonia: an updated meta-analysis based on randomized controlled trials. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1713256
Vancouver
Wu Z, Wu Y, Xiang Z, Qiu Y, Xuan W, Zhang S. The impact of proton pump inhibitor exposure on pneumonia: an updated meta-analysis based on randomized controlled trials. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1713256
BibTeX
@article{Wu2025,
author = {Wu, Zhujun and Wu, Yixuan and Xiang, Zhiyi and Qiu, Yi and Xuan, Wangyi and Zhang, Shengying},
title = {The impact of proton pump inhibitor exposure on pneumonia: an updated meta-analysis based on randomized controlled trials},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1713256}
}
EUVIMED